Download the Tech Updates highlighting vector biology and control news, publications and resources.
Given the breadth of vector control-related literature, we are unable to include all relevant work. These updates are intended to focus primarily on Anopheles biology and a subset of control topics with global relevance. Any views expressed in the updates do not necessarily reflect the views or opinions of IVCC. In many cases, we directly quote sections of published work. Mention of trade names or commercial products is solely for the purpose of providing specific information and does not imply recommendation or endorsement by IVCC or its funders.
Goodbye Malaria – empowering women in Malaria programmes 22nd June 2022Goodbye Malaria is an initiative started by African entrepreneurs who believe that today’s generation can create innovative solutions to the continent’s problems and ultimately change the way the world sees Africa. Since the turn of the century, vector control has proven to be one of the most effective strategies for reducing malaria incidence and deaths. Since 2000, more than 80% of the reduction in malaria prevalence in Africa can be attributed to indoor residual spraying (IRS) and insecticide-treated nets (ITNs).
Traditionally, men have been responsible for implementing IRS in sub-Saharan Africa. However, this traditional view is increasingly being challenged as more organisations recognize that women should play a more significant role in conducting and leading spray operations.
Download our booklet to read more.
Bite prevention tools significantly protect against landing in Cambodia field trial 17th May 2022Recent entomological field results from Project BITE under IVCC’s Indo-Pacific Initiative (IPI) have shown that forest packs containing bite prevention tools offer significant protection from landing mosquitoes. The results come from trials that UCSF-MEI, IVCC’s lead partner on BITE, conducted in Mondulkiri province, Cambodia, with the local non-profit Health Forefront Organization.
The entomological trials were conducted in an area directly adjacent to forest and was comprised of 7 temporary shelters designed to mimic short-term dwellings used by people when working or travelling in the forest. Inside each shelter, one of the bite prevention tools, or a combination of all tools, or a control, were used while volunteers collected mosquitoes via Human Landing Catches (HLC) over a 12-hour period.
Over 49 nights of collections, the entomological field study demonstrated that all products – both on their own and in combination – are highly efficacious at preventing mosquitoes from landing. In fact, all products and combinations reduced mosquito landings by at least 60% compared to the control, while the spatial repellent alone and the combination of all products reduced landings by approximately 95%.
Project BITE aims to evaluate the effectiveness of forest packs containing a spatial emanator, topical repellent, and insecticide-treated clothing when deployed to forest dwellers, goers, and rangers in the Greater Mekong Subregion (GMS). Semi-field trials completed in Thailand in 2021 demonstrated that bite prevention tools not only prevent mosquitoes from landing but can also kill and delay host-seeking.
Following the entomological field studies, Project BITE is currently planning on how best to scale-up use of these tools and further evaluate their epidemiological impact, acceptability, use and cost-effectiveness among high-risk forest-exposed populations.
IVCC and its partners are hopeful that the evidence generated by BITE will help make the case to national programmes and donors on the effectiveness of bite prevention tools delivered in forest packs in the fight against outdoor malaria transmission.
Mitsui’s VECTRON™ T500 under assessment by WHO-PQT/VCP 1st April 2022IVCC would like to congratulate MCAG on the news that their application (P-03226) has been submitted to the WHO-PQT/VCP for the assessment of its new Indoor Residual Spray product, VECTRON™ T500.
This proposed new vector control product contains the world’s first meta-diamide insecticide, TENEBENAL™ (ISO common name: broflanilide) Discovered by MCAG, TENEBENAL™ belongs to Group 30 (GABA-gated chloride channel allosteric modulators) in the IRAC classification. With its new mode of action, it will be an important addition to the vector control toolbox for IRS and can be used in rotation with other IRS products for insecticide resistance management.
In laboratory trials conducted at the Liverpool School of Tropical Medicine[1], and in experimental hut studies supported by IVCC in Burkina Faso, Benin[2] and Tanzania[3], the application of VECTRON™ T500 at 100 mg a.i./m2 demonstrated good residual efficacy for six months or more against susceptible and resistant mosquito strains on mud and other wall surfaces.
[1] Lees, R.S. et al. TENEBENAL™: a meta-diamide with potential for use as a novel mode of action insecticide for public health. Malar J 19, 398 (2020).
[2] Ngufor, C. et al. Efficacy of broflanilide (VECTRON™ T500), a new meta-diamide insecticide, for indoor residual spraying against pyrethroid-resistant malaria vectors. Sci Rep 11, 7976 (2021).
[3] Snetselaar J., et al. Efficacy of indoor residual spraying with broflanilide (TENEBENAL™), a novel meta-diamide insecticide, against pyrethroid-resistant anopheline vectors in northern Tanzania: An experimental hut trial. PLoS ONE 16(3) (2021).
Evidence base to support a WHO policy recommendation for Interceptor® G2 grows 25th January 2023IVCC welcomes the publication in The Lancet of the 24-month results of an epidemiological trial in Benin, to assess the public health value of two dual active ingredient insecticide treated nets (ITNs).
The research was conducted by the London School of Hygiene and Tropical Medicine (LSHTM) in partnership with the Centre de Recherche Entomologique de Cotonou (CREC).
Over the two-year study, in an area of Benin with pyrethroid-resistant mosquitoes, BASF’s Interceptor® G2 (IG2) chlorfenapyr-pyrethroid ITNs provided greater protection from malaria compared to pyrethroid-only nets.
The results show a 46% reduction in malaria incidence in children 6 months to 10 years. Participants of any age had 43% and 39% lower odds of malaria infection at 6 and 18 months after ITN distribution.
This study follows the publication of a sister epidemiological trial carried out in Tanzania and published in The Lancet in 2022. The results of the randomised control trial (RCT) also demonstrated significant reduction in malaria prevalence over a 24-month period, with a reported case incidence reduction of 44% .
“Mosquitoes are becoming increasingly resistant to the pyrethroid insecticides used on insecticidal treated nets,” explains Professor Akogbeto, co-author of the study and Medical Entomologist at CRER in Benin, “this reduces the nets’ ability to protect people from malaria, so we must continue to develop and test new tools that have proven public health value and extend the effectiveness of existing tools against resistant mosquitoes.”
The newly published Benin study confirms the significance of chlorfenapyr as an ITN treatment to control malaria in areas with pyrethroid-resistant vectors, compared to pyrethroid-only ITNs. In both trials, analysis also indicates that individuals living in the chlorfenapyr-pyrethroid group benefitted, regardless of whether they were using a study net, suggesting a community impact of the net.
The results of the Benin study provided vital second-trial evidence that will enable the World Health Organization (WHO) to make policy recommendations on this new ITN class.
Nick Hamon, former IVCC CEO says: “Combined, the results of the epidemiological trials in Benin and Tanzania provide a robust and cumulative evidence base to support an appropriate WHO policy recommendation for Interceptor® G2. The research shows IG2 nets show a significant reduction in malaria incidence, prevalence and transmission and demonstrate good public health value.”
As during the Tanzania trial, DCT’s RoyalGuard® pyriproxyfen-pyrethroid nets were also tested in the Benin study. While the results indicate RoyalGuard® ITNs did not provide additional protection against malaria infection, there was evidence for an impact to indoor transmission. Lower net use in the RoyalGuard® group could contribute to the lack of impact, more research is needed to fully understand the results.
Both trials have been delivered through the IVCC led New Nets Project (NNP), funded by Unitaid and the Global Fund. The studies will report additional data once the 36-month period is reached and, combined with New Net Pilot evidence pilots across 5 countries, will contribute to the understanding of both Interceptor® G2 and RoyalGuard’s® product performance over time, across various endemicities and resistance profile.
UK-based social finance company MedAccess is supporting access to Interceptor® G2 nets in 14 African countries. The company’s volume guarantee has enabled BASF to reduce the price procurers pay for the nets.
——ends——-
For further information contact:
Laura Roberts, Communications Manager
(+44) 07849 700582
Product and Project information
Interceptor® G2
Interceptor® G2 is a second-generation ITN developed by BASF with a combination of chlorfenapyr and alpha-cypermethrin to control insecticide resistant mosquitoes. This novel mode of action in vector control exploits mosquito enzymatic systems against themselves and shows no cross-resistance to other insecticide classes. Unlike pyrethroids, the chlorfenapyr target site of activity is not the insect nervous system. Instead, chlorfenapyr acts, after being metabolized by P450 enzymes at the cellular level, by disrupting respiratory pathways and proton gradients through the uncoupling of oxidative phosphorylation within the mitochondria. The Interceptor® G2 net has a WHO prequalification listing. https://www.who.int/pq-vector-control/prequalified-lists/interceptor_g2/en/ Previously the net was evaluated and given an interim recommendation by the 20th WHOPES Working Group.
Royal Guard®
Royal Guard® is an ITN developed by Disease Control Technologies to provide vector control through both the personal protection of traditional mosquito knockdown and mortality, as well as a reduction in fecundity of any mosquitoes that manage to survive exposure to the products pyrethroid active ingredient. The intended benefit of the insect growth regulator, pyriproxyfen, is to reduce the fecundity of adult female mosquitoes and, therefore, yield an overall reduction in the vector population by inhibiting egg laying, larval-pupal transformation and the emergence of functioning young adult mosquitos. The Royal Guard® net has a WHO prequalification listing. https://www.who.int/pq-vector-control/prequalified-lists/RoyalGuard/en/
The New Nets Project (NNP)
The Global Fund and Unitaid are each investing US$33 million between 2018 to 2022 to introduce new insecticide-treated nets to fight malaria-carrying mosquitoes. The New Nets Project is working to build the evidence base around, and prime the market for, the next generation of nets, which are treated with two different types of insecticide to help improve control of mosquitoes.
The project will generate evidence on the efficacy and cost-effectiveness of the new dual insecticide nets to inform a WHO policy decision on dual-AI nets and guide decision-making around product procurement at the country level. It is expected that the New Nets Project – with its unique design of parallel collection of epidemiological data and cost-effectiveness studies – will significantly reduce the timeline for entry of the new nets into the market.
The U.S. President’s Malaria Initiative and the Bill & Melinda Gates Foundation are key operational and financial partners. A coalition led by IVCC is implementing the project which includes The Alliance for Malaria Prevention, Imperial College London, The Liverpool School of Tropical Medicine, PATH, PSI and Tulane University.
IVCC
IVCC is the only Product Development Partnership (PDP) working in vector control. IVCC was established in 2005, through an initial $50million grant to the Liverpool School of Tropical Medicine (LSTM) from the Bill & Melinda Gates Foundation and has since provided ongoing support for IVCC activities. As a registered charity in the UK, IVCC is also funded by UK Aid, USAID and the Swiss Agency for Development and Cooperation to work with stakeholders to facilitate the development of novel and improved public health insecticides and formulations to combat the rapidly growing problem of insecticide resistance. In addition, IVCC is also funded by Unitaid and the Global Fund to implement catalytic market access projects, such as NgenIRS and the New Nets Project which support the rapid and scaled deployment of innovative vector control interventions. IVCC brings together partners from industry, the public sector and academia to create new solutions to prevent disease transmission. By focusing resources and targeting practical scientific solutions we accelerate the process from innovation to impact.
Featured image credit: PSI, Mali